Sign In
Buy SRDX
$42.83
+1.22 (+2.93%)
At Close: Nov 17, 2025
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
06:00am, Monday, 17'th Nov 2025
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health car
Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge
12:00pm, Tuesday, 11'th Nov 2025
The United States District Court for the Northern District of Illinois on Tuesday denied a request by the U.S. Federal Trade Commission and certain state regulators to issue a preliminary injunction t
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
07:00pm, Monday, 10'th Nov 2025
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health car
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that result
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Se
Contrasting Surmodics (NASDAQ:SRDX) and Guided Therapeutics (OTCMKTS:GTHP)
01:14am, Monday, 20'th Oct 2025
Surmodics (NASDAQ: SRDX - Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two compan
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
02:06pm, Tuesday, 12'th Aug 2025
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
11:01am, Friday, 08'th Aug 2025
Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street
SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates
09:16am, Friday, 08'th Aug 2025
SurModics (SRDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $0.27 per share a year ago.
Surmodics (SRDX) Q3 EPS Turns Positive
07:12am, Friday, 08'th Aug 2025
Surmodics (SRDX) Q3 EPS Turns Positive
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
07:00am, Friday, 08'th Aug 2025
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?
12:37pm, Friday, 30'th May 2025
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
01:50pm, Thursday, 01'st May 2025
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say
11:00am, Wednesday, 30'th Apr 2025
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates
09:20am, Wednesday, 30'th Apr 2025
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.07 per share a year ago.
